NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have earned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $48.00.

NAMS has been the topic of several research analyst reports. Royal Bank Of Canada lifted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th.

Insider Activity

In other news, Director Louis G. Lange sold 44,619 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the transaction, the director directly owned 10,360 shares in the company, valued at $315,151.20. The trade was a 81.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the transaction, the insider owned 69,302 shares in the company, valued at approximately $2,099,850.60. This represents a 60.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,168,286 shares of company stock worth $38,211,967 in the last ninety days. Corporate insiders own 20.84% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN lifted its stake in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of NewAmsterdam Pharma by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after purchasing an additional 437 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of NewAmsterdam Pharma by 3.8% in the 3rd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after purchasing an additional 483 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of NewAmsterdam Pharma by 5.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after purchasing an additional 544 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in shares of NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $38.73 on Friday. NewAmsterdam Pharma has a twelve month low of $16.78 and a twelve month high of $42.00. The stock has a market cap of $4.45 billion, a price-to-earnings ratio of -21.64 and a beta of 0.02. The firm’s 50 day moving average price is $31.77 and its two-hundred day moving average price is $34.24.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 25.90% and a negative net margin of 943.23%.The firm had revenue of $3.04 million for the quarter. On average, research analysts forecast that NewAmsterdam Pharma will post -1.81 EPS for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.